Compare Stocks

Date Range: 

 OcugenForma TherapeuticsCullinan OncologyAlloVirAligos Therapeutics
SymbolNASDAQ:OCGNNASDAQ:FMTXNASDAQ:CGEMNASDAQ:ALVRNASDAQ:ALGS
Price Information
Current Price$7.40$25.82$26.03$21.47$26.94
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.21.71.81.71.7
Analysis Score1.13.53.53.53.5
Community Score3.23.33.83.23.2
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.71.71.7
Earnings & Valuation Score1.90.00.00.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$7.88$59.83$51.75$49.25$34.50
% Upside from Price Target6.42% upside131.73% upside98.81% upside129.39% upside28.06% upside
Trade Information
Market Cap$1.47 billion$1.22 billion$1.13 billion$1.40 billion$1.03 billion
Beta4.47N/AN/AN/AN/A
Average Volume67,482,242419,862270,340324,06680,048
Sales & Book Value
Annual Revenue$42.62 million$100.56 millionN/A$170,000.00N/A
Price / Sales34.4212.16N/A8,222.63N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.13 per share$13.72 per share($1.84) per share$5.42 per share$6.01 per share
Price / Book56.921.88N/A3.96N/A
Profitability
Net Income$-21,820,000.00$-70,410,000.00$-51,800,000.00$-69,780,000.00$-108,540,000.00
EPS($0.31)($3.22)($5.48)($2.59)($10.87)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E Ratio2.78N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-102.82%-22.20%N/AN/AN/A
Return on Assets (ROA)-79.52%-20.94%N/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.04%N/AN/AN/AN/A
Current Ratio12.00%20.10%45.21%21.91%8.71%
Quick Ratio12.00%20.10%45.21%21.91%8.71%
Ownership Information
Institutional Ownership Percentage12.47%85.57%71.97%40.94%70.84%
Insider Ownership Percentage3.40%4.32%21.78%55.12%15.10%
Miscellaneous
Employees15114247474
Shares Outstanding198.23 million47.37 million43.52 million65.11 million38.15 million
Next Earnings Date8/13/2021 (Estimated)8/12/2021 (Estimated)8/13/2021 (Estimated)9/1/2021 (Estimated)8/9/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 7.3%Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 7.3%
americanbankingnews.com - June 14 at 2:06 PM
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 7.3%Aligos Therapeutics (NASDAQ:ALGS) Trading Down 7.3%
americanbankingnews.com - June 14 at 2:06 PM
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
finance.yahoo.com - June 14 at 1:04 PM
Head-To-Head Contrast: Aligos Therapeutics (ALGS) & Its RivalsHead-To-Head Contrast: Aligos Therapeutics (ALGS) & Its Rivals
americanbankingnews.com - June 13 at 1:08 PM
Aligos Therapeutics (ALGS) & Its Rivals Critical AnalysisAligos Therapeutics (ALGS) & Its Rivals Critical Analysis
americanbankingnews.com - June 12 at 9:22 AM
Aligos Therapeutics (NASDAQ:ALGS) Trading 7.4% Higher Aligos Therapeutics (NASDAQ:ALGS) Trading 7.4% Higher
americanbankingnews.com - June 11 at 1:44 PM
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $29.89Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $29.89
americanbankingnews.com - June 10 at 12:36 PM
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG ConferenceAligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference
finance.yahoo.com - June 10 at 8:29 AM
Head-To-Head Contrast: Aligos Therapeutics (ALGS) versus Its CompetitorsHead-To-Head Contrast: Aligos Therapeutics (ALGS) versus Its Competitors
americanbankingnews.com - June 7 at 7:14 AM
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 4.9%Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 4.9%
americanbankingnews.com - June 3 at 12:48 PM
Critical Comparison: Aligos Therapeutics (ALGS) & The CompetitionCritical Comparison: Aligos Therapeutics (ALGS) & The Competition
americanbankingnews.com - June 3 at 11:24 AM
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 6%Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 6%
americanbankingnews.com - June 2 at 2:44 PM
NASH crash hits another Bay Area fatty liver drug hopefulNASH crash hits another Bay Area 'fatty liver' drug hopeful
bizjournals.com - May 24 at 6:04 PM
Aligos Therapeutics to Present at the Jefferies  Virtual Healthcare ConferenceAligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 20 at 6:38 PM
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial ResultsAligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 9:02 PM
Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021
finance.yahoo.com - May 5 at 12:11 PM
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of DirectorsAligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
finance.yahoo.com - April 27 at 7:16 PM
Aligos Therapeutics Inc (ALGS)Aligos Therapeutics Inc (ALGS)
investing.com - April 22 at 1:04 PM
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in ...Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in ...
apnews.com - April 14 at 1:09 PM
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept StudyAligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
finance.yahoo.com - April 14 at 8:09 AM
Heres Why Were Not Too Worried About Aligos Therapeutics (NASDAQ:ALGS) Cash Burn SituationHere's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
nasdaq.com - April 6 at 6:47 PM
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ...Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ...
apnews.com - March 23 at 6:33 PM
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsAligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 23 at 6:33 PM
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First ...Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First ...
apnews.com - March 11 at 7:35 AM
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept StudyAligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
finance.yahoo.com - March 10 at 9:00 AM
DateCompanyBrokerageAction
6/11/2021OcugenHC WainwrightLower Price Target
6/10/2021OcugenRoth CapitalDowngrade
6/10/2021OcugenChardan CapitalLower Price Target
5/13/2021OcugenCantor FitzgeraldReiterated Rating
6/11/2021Forma TherapeuticsSVB LeerinkLower Price Target
3/18/2021Forma TherapeuticsOppenheimerReiterated Rating
12/8/2020Forma TherapeuticsCredit Suisse GroupBoost Price Target
7/14/2020Forma TherapeuticsJefferies Financial GroupInitiated Coverage
6/7/2021Cullinan OncologyMorgan StanleyBoost Price Target
2/2/2021Cullinan OncologyEvercore ISIInitiated Coverage
2/11/2021AlloVirPiper SandlerBoost Price Target
8/24/2020AlloVirJPMorgan Chase & Co.Initiated Coverage
1/7/2019AlloVirBank of AmericaUpgrade
7/10/2018AlloVirThe Goldman Sachs GroupInitiated Coverage
(Data available from 6/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.